3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Cholangiocarcinoma
6
Carcinoma, Transitional Cell
5
Acrocephalosyndactylia
5
Neoplasm Metastasis
3
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Miscellaneous
1
Solid Tumor
1
Sarcoma
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
Paclitaxel
34
Carboplatin
27
pembrolizumab
20
Bevacizumab
16
Letrozole
13
Megestrol Acetate
10
Cisplatin
9
lenvatinib
8
olaparib
7
dostarlimab
7
Metformin
7
durvalumab
6
abemaciclib
6
Radiotherapy
6
Everolimus
6
niraparib
5
Specimen Handling
5
Nivolumab
5
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Fluorouracil
5
Docetaxel
5
Biopsy
5
temsirolimus
4
rucaparib
4
Oxaliplatin
4
Fulvestrant
4
Doxorubicin
4
sapanisertib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Endometrial Neoplasms
×
pemigatinib
×
Clear all
NCT04463771
2025-12-10
POD1UM-204
Incyte Corporation
Phase 2
Active not recruiting
206 enrolled